Bavencio

This page shows the latest Bavencio news and features for those working in and with pharma, biotech and healthcare.

NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

Picks up approval as a first-line treatment for advanced cancer. The UK’s National Institute for Health and Care Excellence (NICE) has recommended Merck KGaA and Pfizer’s immunotherapy Bavencio ... Compared to treatment with targeted kinase inhibitor

Latest news

Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer

The partners had been testing Bavencio (avelumab) in untreated, advanced squamous cell carcinoma of the head and neck. ... In the phase 3 JAVELIN trial, Bavencio was being evaluated in combination with chemoradiotherapy (CRT), versus standard of care CRT.
AstraZeneca’s Imfinzi fails first-line bladder cancer test

inhibitors including Bristol-Myers Squibb’s Opdivo (nivolumab) and Merck KGaA/Pfizer’s Bavencio (avelumab). ... Bavencio is closing on a first-line approval however, thanks to positive results in the JAVELIN trial earlier this year which could form
BMS unveils long-term results for Opdivo in kidney cancer

Bavencio plus Inlyta.
NICE turns down Keytruda/Inlyta combo for kidney cancer

Keytruda/Inlyta is however also competing in Europe with the combination of Pfizer/Merck KGaA’s Bavencio (avelumab) with Inlyta, which was approved by the EMA last October and will benefit
Pfizer signs $507m cancer deal with Effector Therapeutics

It has already signed previous collaboration deals with Pfizer and Merck KGaA to study tomivosertib in combination with Bavencio (avelumab) and with Merck &Co to evaluate the candidate with blockbuster

More from news
Approximately 10 fully matching, plus 34 partially matching documents found.

Latest Intelligence

Immuno-oncology in 2019: the rapid evolution continues

In addition to the PD-1 inhibitors Keytruda and Opdivo, there are four PD-L1 inhibitors: Roche’s Tecentriq, AstraZeneca’s Imfinzi, Pfizer and Merck’s Bavencio and Sanofi and ... This is particularly bad news for Pfizer and Merck’s Bavencio, as it
The handover: Pfizer reshapes itself for a new era

The therapy area is dominated by Merck’s Keytruda, BMS’ Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it ... The JAVELIN Renal 101 trial combining Bavencio with Inlyta in
Cancer immunotherapy: What's on the horizon?

They include Pfizer’s OX40 agonist PF-04518600, in early-stage testing in combination with the company’s Bavencio (avelumab) and targeted cancer drug Inlyta (axitinib) as well as chemotherapy,